TMC Venture Fund — 2024 Investments
2 investments dated 2024 · listed companies and verified rows first · show all
CrossBridge Bio, launched in 2023, develops next-generation antibody-drug conjugates (ADCs) to address a range of cancer indications.
BiotechHealthtechHouston, US
Kyoji Tsuchikama(Executive Officer, Director, Promoter)Michael Torres(Executive Officer, Director, Promoter)
BoardWilliam F. McKeon(Director)Damir Illich(Director)Patrick James Crutcher(Director)
Motif Neuro develops neural devices to monitor and regulate mental health and performance, with an initial focus on treatment-resistant depression using bioelectronic implants called DOT that are deployed via outpatient procedure.
BiotechDigital HealthHealthtechMedical DevicesHouston, US
Anthony Arnold(Director)Thomas M. Shehab(Director)
BoardJacob Robinson(Executive Officer, Director)Amy Kruse(Director)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.